NASDAQ · TLSI
TriSalus Life Sciences, Inc.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
Loading market information…
NASDAQ · NNOX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nano-X Imaging Ltd.’s quoted price sits in the lower half of its reported 52-week range, 93.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nano-X Imaging Ltd.’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nano-X Imaging Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 22, 2025 | -$0.21-10.53% vs estimate | $2.82M-17.21% vs estimate |
|---|
| Q4 2024 | Mar 31, 2025 | -$0.23-1.47% vs estimate | $3.00M-21.05% vs estimate |
|---|
| Q3 2024 | Nov 21, 2024 | -$0.23-4.55% vs estimate | $3.03M-20.24% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $3.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$5.86+$0.08 (+1.38%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
$7.26+$0.01 (+0.14%)
Inogen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.09% below the high.
$1.73+$0.02 (+1.17%)
MaxCyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.42% below the high.
$3.15+$0.03 (+0.8%)
Quanterix Corporation’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$1.79-$0.01 (-0.56%)
Health Catalyst, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$1.17-$0.08 (-6.02%)
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
$2.26-$0.03 (-1.31%)
Solana Company’s quoted price sits in the lower half of its reported 52-week range, 66.27% below the high.
